Saudi Arabia Saudi Arabia’s ambitious Vision 2030 economic transformation plan aims at transitioning the Middle East’s largest economy away from an over-reliance on fossil fuels and into a more diversified modern nation. This transition is being felt especially keenly in healthcare, where the Ministry of Health’s functions are shifting with the aim…
Denmark Copenhagen Capacity is Greater Copenhagen’s official organization for investment, promotion, and business development. Its CEO/managing director, Asbjørn Overgaard, outlines the fundamentals attracting life sciences firms to the region, stakeholders’ key investment concerns, and the work still to be done on closer alignment with neighbouring Sweden. Our goals are threefold:…
Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…
Denmark Peter Huntley of Medicoindustrien, the industry association for Danish medtech, outlines his vision for the industry, including why a shift to broad, value-based pricing will better establish Denmark as a bastion of high quality and high value impact medical devices. [Denmark] has a prosperous future ahead if the divided…
Saudi Arabia Prof. Ahmed Aljedai, assistant deputy minister of therapeutic affairs for support services at Saudi Arabia’s Ministry of Health (MoH) outlines how the Saudi healthcare system is being restructured in line with the country’s Vision 2030 economic transformation programme and the three goals of improving access, improving quality, and improving value.…
Turkey After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence of chronic disease, strong national immunization program and increasing life expectancy. Its general manager for the Turkey cluster, Gözde Güllüoğlu,…
Pharma Legal Handbook Cannabinoid drugs, medicinal cannabis and opioid drugs in Malaysia – a comprehensive legal overview. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. CANNABINOID DRUGS 1. Are Cannabinoid Drugs authorized in…
Pharma Legal Handbook An insight into regulatory reforms in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. Are there proposals for reform or significant change to the healthcare system? The…
Pharma Legal Handbook The key facts about patents and trademarks in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What are the basic requirements to obtain patent and trademark protection?…
Pharma Legal Handbook All legal aspects surrounding product liability in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What types of liability are recognized in your jurisdiction? Product liability for…
Pharma Legal Handbook A brief overview of the situation regarding traditional medicines and OTC products in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What are the regulatory requirements for…
Pharma Legal Handbook All about marketing, manufacturing, packaging & labeling, advertising in Malaysian Pharma. Prepared in association with Skrine, a leading law firm in Malaysia, this is an extract from The Pharma Legal Handbook: Malaysia, available to purchase here for GBP 99. 1. What is the authorization process for the marketing of new…
See our Cookie Privacy Policy Here